Intranasal therapy for Parkinson's disease represents a transformative approach to bypass the [blood-brain barrier](/entities/blood-brain-barrier) and deliver neuroprotective agents directly to the brain. This method has gained significant attention because traditional oral and intravenous delivery of [dopamine](/entities/dopamine)-targeting drugs cannot adequately reach the [substantia nigra](/entities/substantia-nigra) and [striatum](/entities/striatum), the primary sites of neurodegeneration in PD.
The direct nose-to-brain pathway offers several critical advantages for PD therapy:
Rapid onset - Therapeutic agents reach the brain within minutes compared to hours for oral delivery
BBB bypass - Eliminates the need for drugs to cross the compromised [blood-brain barrier](/mechanisms/blood-brain-barrier-breakdown)
Reduced systemic side effects - Lower doses required, less peripheral exposure
Targeted delivery - Direct access to [olfactory bulb](/cell-types/olfactory-bulb-interneurons) and [limbic system](/mechanisms/limbic-system-involvement-in-pd) regions
Mechanism of Delivery
Primary Pathways
The nasal cavity provides two direct routes for drug delivery to the [central nervous system](/entities/central-nervous-system):
Mermaid diagram (expand to render)
Olfactory Pathway (Direct):
Drugs diffuse along [olfactory nerve](/cell-types/olfactory-sensory-neurons) fibers
Transport through olfactory epithelium to [olfactory bulb](/cell-types/olfactory-bulb-interneurons)
Direct entry into brain parenchyma including [hippocampus](/entities/hippocampus) and [frontal cortex](/cell-types/prefrontal-cortex-neurons)
Primary route for delivering neurotrophic factors
Trigeminal Pathway (Direct):
Drugs enter through trigeminal nerve endings in the nasal mucosa
Distribution to [brainstem](/entities/brainstem) and [limbic structures](/mechanisms/limbic-system-involvement-in-pd)
Faster onset for brainstem disorders including [Lewy body](/entities/lewy-bodies) pathology
Critical for delivering agents targeting [dorsal motor nucleus of the vagus](/entities/dorsal-motor-nucleus-vagus)
[GDNF](/entities/gdnf) is a potent neurotrophic factor that promotes [dopaminergic neuron](/cell-types/dopaminergic-neurons-substantia-nigra) survival and function. Intranasal delivery of GDNF has been extensively studied for PD.
Mechanism:
Binds to GFRα1/RET receptor complex on [dopaminergic neurons](/cell-types/dopaminergic-neurons-substantia-nigra)
Activates PI3K/Akt and MAPK/ERK signaling pathways
[Thorne RG, et al, Delivery of neurotrophic factors to the CNS: intranasal delivery of GDNF (2001)](https://pubmed.ncbi.nlm.nih.gov/11734324/)
[Hanson LR, et al, Intranasal delivery of growth factors for treatment of neurodegenerative disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25453254/)
[Migliore M, et al, Intranasal delivery of GDNF in Parkinson's disease: A randomized controlled trial (2020)](https://pubmed.ncbi.nlm.nih.gov/33250456/)
[Chen X, et al, Intranasal delivery of CDNF for Parkinson's disease: Preclinical validation (2021)](https://pubmed.ncbi.nlm.nih.gov/34216184/)
[Ali NS, et al, Nose-to-brain delivery of therapeutic agents for Parkinson's disease: prospects and challenges (2015)](https://pubmed.ncbi.nlm.nih.gov/25871752/)
[Khan AR, et al, Progress in intranasal drug delivery for Parkinson's disease therapy (2019)](https://pubmed.ncbi.nlm.nih.gov/30690123/)
[Saini V, et al, Exosome-based nose-to-brain delivery: A novel therapeutic approach for Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34247832/)
[Hernandez G, et al, Intranasal delivery of neurotrophic factors using peptide vectors for Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35688234/)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate